Creating zebrafish models to study human cancer and blood cell therapies.
Developing preclinical xenograft models in zebrafish.
This study is working on using special zebrafish to better understand human cancers and blood cell treatments, so researchers can see how these cells act in real time and find new ways to help people with cancer and other blood-related conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11036248 on NIH RePORTER |
What this research studies
This research focuses on developing advanced zebrafish models that can be used to study human cancers and blood cell therapies. By utilizing immune-deficient zebrafish, researchers aim to transplant human cancer cells and blood cells, allowing for real-time imaging and assessment of how these cells behave in a living organism. This innovative approach seeks to provide a more cost-effective and efficient method for studying the effects of various treatments, including drugs and immunotherapies, on human cells. The ultimate goal is to create a universal model that can be used for a wide range of regenerative and cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers or blood disorders who may benefit from innovative treatment approaches.
Not a fit: Patients with conditions unrelated to cancer or blood disorders may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cancer and blood disorders by providing better models for testing therapies.
How similar studies have performed: Previous research has shown success in using zebrafish models for studying human diseases, indicating a promising avenue for this approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Langenau, David Michael — Massachusetts General Hospital
- Study coordinator: Langenau, David Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.